Table. Fifteen-Year Incidence of DM, PCSM, and ACM in Patients With FIR vs UIR Prostate Cancer Receiving ADT or Not.
| 15-y Incidence, % | HR (95% CI)a | P value | |
|---|---|---|---|
| UIR vs FIR | |||
| DM | 17 vs 6 | 2.36 (1.44-3.89) | .001 |
| PCSM | 20 vs 11 | 1.84 (1.29-2.62) | .001 |
| ACM | 69 vs 61 | 1.19 (1.02-1.40) | .03 |
| ADT vs no ADT | |||
| DM: FIR | 8 vs 5 | 1.55 (0.64-3.74) | .33 |
| PCSM: FIR | 9 vs 14 | 0.63 (0.35-1.15) | .13 |
| ACM: FIR | 62 vs 60 | 1.02 (0.80-1.30) | .90 |
| DM: UIR | 10 vs 24 | 0.48 (0.28-0.83) | .008 |
| PCSM: UIR | 12 vs 28 | 0.40 (0.26-0.60) | <.001 |
| ACM: UIR | 66 vs 71 | 0.84 (0.68-1.03) | .09 |
Abbreviations: ACM, all-cause mortality; ADT, androgen deprivation therapy; DM, distant metastasis; FIR, favorable intermediate-risk; HR, hazard ratio; PCSM, prostate cancer–specific mortality; UIR, unfavorable intermediate-risk.
a
HRs and 95% CIs are calculated with Cox regression for ACM and the Fine and Gray method for DM and PCSM.